Skip to main content
SpringerLink
Log in

Adalimumab

Multiple sclerosis, central and peripheral nervous system demyelinating disease and impaired cerebellar function: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Gharib MH, et al. Demyelinating neurological adverse events following the use of adalimumab. Rheumatology 58 (Suppl. 3): iii172 abstr. E030, Apr 2019. Available from: URL: http://doi.org/10.1093/rheumatology/kez110.029 [abstract] - Qatar

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab. Reactions Weekly 1763, 21 (2019). https://doi.org/10.1007/s40278-019-65113-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-65113-y

Search

Navigation